SPARK Norway Educational Forum: Early phase production

Procedures that work in the lab don’t always scale-up seamlessly into production in the life science industry. Process development while staying compliant will be required. What should be considered when you work in lab-scale to make the transition to production smoother? What are the common pitfalls, and what are the dos and don’ts?

The meeting is part of the SPARK Norway Educational Forum Series 3: Therapeutics and diagnostics – monthly open meetings organized by UiO:Life Science and SPARK Norway partners.

Please fill out the form at the bottom of this page to sign up.


Two highly experienced life science industry executives will share some of their experience on how to successfully transform your lab-scale protocols into early phase production.

  • Astrid Hilde Myrset, PhD
    CEO, Catapult Life Science AS

    Astrid has a PhD in biochemistry from the University of Oslo (UiO). From 1994–2008 she had different positions in the RD organization of Nycomed-Amersham-GE, including project leader, knowledge manager and innovation leader. From 2008–2012 she was CEO in the startup Omegatri AS, and from 2012–2017 she was director of clinical and pre-clinical research at AlgiPharma AS.

    Astrid was one of the founders of Catapult Life Science in 2016 and has for the last 3 years served as CEO.
  • Bjørn Pedersen
    Managing Director, Diatec Monoclonals AS

    Bjørn studied Biochemistry and Cell Biology at UiO. Since 1974 he worked in A/S E. Pedersen & Sønn, distributing laboratory supplies in Norway and Denmark. In 1988 he founded Diatec Monoclonals AS. A/S E. Pedersen & Sønn was sold to Thermo Fisher in 2008 and he was a part of Fisher Scientific European Management Team until 2012.

    Bjørn has worked full time in Diatec Monoclonals since 2013. He has more than 30 years’ experience in sales and marketing, negotiations and international business.



UiO:Life Science
Published June 17, 2019 3:35 PM - Last modified Oct. 9, 2019 11:12 AM